Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Antibody patterns may predict inflammatory bowel disease years before diagnosis (opens in a new tab)

news-medical.net · 2026-10-19

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

One key claim is not backed by the study. 4 other points were not covered by the paper.

  • 1 supported
  • 1 not supported
  • 4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

One claim isn't supported by the study. One of six checks out. Four claims the study doesn't address.

  • 1 supported
  • 1 not supported
  • 4 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not supportedCompared with healthy controls, antibody diversity was significantly lower in people who later developed Crohn's disease or ulcerative colitis, with distinct antibody responses evident up to 10 years before diagnosis.View evidenceHide evidence

As statedup to 10 years before diagnosis

Why this verdict

The abstract-level profile supports distinct antibody responses/signatures before diagnosis, including signals detectable up to 10 years for CD and UC-related signatures. But it does not support the claim that antibody diversity was significantly lower; instead, the profile reports increased antibody-repertoire variability up to about 4 years before diagnosis. The stated direction and the word “significantly” are not supported by the supplied profile.

1

Study evidence

Antibody-repertoire variability was increased up to ~4 years before diagnosis in individuals who later developed Crohn's disease and ulcerative colitis.

“We applied PhIP-Seq to profile antibody responses in 2000 longitudinal serum samples from 200 individuals who developed Crohn's disease (CD), 200 who developed ulcerative colitis (UC) and 100 matched healthy controls”
2

Study evidence

Herpesvirus-directed antibody responses, notably Epstein–Barr virus (EBV)-directed antibodies, were elevated in individuals who later developed Crohn’s disease, detectable up to 10 years before diagnosis and especially prominent in those who later developed complicated or ileal disease.

“Differential analyses revealed elevated herpesvirus-directed responses (notably Epstein-Barr virus) and anti-flagellin antibodies up to 10 years prediagnosis in CD, particularly in individuals who later developed complicated or ileal disease.”
Claim 2 of 6Not coveredResearchers analyzed 2,000 serum samples from 500 people, including 200 who developed Crohn's disease, 200 who developed ulcerative colitis, and 100 age- and sex-matched healthy controls, with samples collected at diagnosis and about two, four, and 10 years earlier.View evidenceHide evidence

As stated2,000 serum samples from 500 individuals

Why this verdict

The profile supports the sample counts—2,000 longitudinal serum samples from 200 future Crohn’s disease cases, 200 future ulcerative colitis cases, and 100 matched healthy controls—and collection up to 10 years before diagnosis. However, the abstract-level profile does not verify that controls were specifically age- and sex-matched, nor the exact sampling schedule of diagnosis and about two, four, and 10 years earlier. Those details require fuller evidence than supplied here.

1

Study evidence

Antibody-repertoire variability was increased up to ~4 years before diagnosis in individuals who later developed Crohn's disease and ulcerative colitis.

“We applied PhIP-Seq to profile antibody responses in 2000 longitudinal serum samples from 200 individuals who developed Crohn's disease (CD), 200 who developed ulcerative colitis (UC) and 100 matched healthy controls”
Claim 3 of 6Not coveredMachine-learning models integrating the early antibody signatures discriminated future Crohn's disease and ulcerative colitis cases from healthy controls up to 10 years before diagnosis, with AUC values of 0.90 and 0.84, respectively.View evidenceHide evidence

As statedAUC 0.90 for Crohn's disease and 0.84 for ulcerative colitis

Why this verdict

The profile supports that prediagnostic antibody signatures were identified in future CD and UC cases versus controls. It does not report machine-learning models, discrimination analyses, or AUC values of 0.90 and 0.84. At abstract depth, these prediction-performance details cannot be verified.

1

Study evidence

Antibody-repertoire variability was increased up to ~4 years before diagnosis in individuals who later developed Crohn's disease and ulcerative colitis.

“We applied PhIP-Seq to profile antibody responses in 2000 longitudinal serum samples from 200 individuals who developed Crohn's disease (CD), 200 who developed ulcerative colitis (UC) and 100 matched healthy controls”
2

Study evidence

Herpesvirus-directed antibody responses, notably Epstein–Barr virus (EBV)-directed antibodies, were elevated in individuals who later developed Crohn’s disease, detectable up to 10 years before diagnosis and especially prominent in those who later developed complicated or ileal disease.

“Differential analyses revealed elevated herpesvirus-directed responses (notably Epstein-Barr virus) and anti-flagellin antibodies up to 10 years prediagnosis in CD, particularly in individuals who later developed complicated or ileal disease.”
Claim 4 of 6Not coveredThe profiles also differentiated people who later developed complicated from non-complicated Crohn's disease up to approximately 10 years before diagnosis, with an AUC of 0.85.View evidenceHide evidence

As statedAUC 0.85

Why this verdict

The profile supports a qualitative association between prediagnostic CD antibody signatures—especially herpesvirus/EBV-directed and anti-flagellin responses—and later complicated or ileal Crohn’s disease. It does not verify a model that differentiated complicated from non-complicated CD, nor an AUC of 0.85. The performance metric and exact discrimination claim are not verifiable from the abstract-level profile.

1

Study evidence

Herpesvirus-directed antibody responses, notably Epstein–Barr virus (EBV)-directed antibodies, were elevated in individuals who later developed Crohn’s disease, detectable up to 10 years before diagnosis and especially prominent in those who later developed complicated or ileal disease.

“Differential analyses revealed elevated herpesvirus-directed responses (notably Epstein-Barr virus) and anti-flagellin antibodies up to 10 years prediagnosis in CD, particularly in individuals who later developed complicated or ileal disease.”
Claim 5 of 6Not coveredThe authors said the findings are an important proof of principle but need validation in independent, more diverse, prospectively followed populations before they could be translated into a clinical screening test.View evidenceHide evidence

Why this verdict

The caution is broadly consistent with the profile’s limitations, including abstract-only reporting, uncertain generalisability beyond the US military cohort, lack of assay-performance information, and absence of independent validation details. However, the supplied profile does not contain the quoted “proof of principle” wording or the specific author statement about translation into a clinical screening test, so the claim as attributed is not verifiable at this depth.

1

Study evidence

Antibody-repertoire variability was increased up to ~4 years before diagnosis in individuals who later developed Crohn's disease and ulcerative colitis.

“We applied PhIP-Seq to profile antibody responses in 2000 longitudinal serum samples from 200 individuals who developed Crohn's disease (CD), 200 who developed ulcerative colitis (UC) and 100 matched healthy controls”
2

Study evidence

Herpesvirus-directed antibody responses, notably Epstein–Barr virus (EBV)-directed antibodies, were elevated in individuals who later developed Crohn’s disease, detectable up to 10 years before diagnosis and especially prominent in those who later developed complicated or ileal disease.

“Differential analyses revealed elevated herpesvirus-directed responses (notably Epstein-Barr virus) and anti-flagellin antibodies up to 10 years prediagnosis in CD, particularly in individuals who later developed complicated or ileal disease.”
Claim 6 of 6SupportedA large-scale study presented at UEG Week 2026 identified distinct antibody patterns up to 10 years before diagnosis of inflammatory bowel disease (IBD).View evidenceHide evidence

As statedup to 10 years before diagnosis

Why this verdict

The abstract-level profile supports the core headline claim: a large longitudinal PhIP-Seq serology study found disease-specific antibody/serological signatures in future IBD cases, with CD- and UC-related signals described in samples collected up to 10 years before diagnosis. The specific conference framing, “presented at UEG Week 2026,” is not independently verifiable from the supplied paper profile, but the scientific substance of the claim is supported.

1

Study evidence

Antibody-repertoire variability was increased up to ~4 years before diagnosis in individuals who later developed Crohn's disease and ulcerative colitis.

“We applied PhIP-Seq to profile antibody responses in 2000 longitudinal serum samples from 200 individuals who developed Crohn's disease (CD), 200 who developed ulcerative colitis (UC) and 100 matched healthy controls”
2

Study evidence

Herpesvirus-directed antibody responses, notably Epstein–Barr virus (EBV)-directed antibodies, were elevated in individuals who later developed Crohn’s disease, detectable up to 10 years before diagnosis and especially prominent in those who later developed complicated or ileal disease.

“Differential analyses revealed elevated herpesvirus-directed responses (notably Epstein-Barr virus) and anti-flagellin antibodies up to 10 years prediagnosis in CD, particularly in individuals who later developed complicated or ileal disease.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The abstract reports increased antibody-repertoire variability up to about 4 years before diagnosis in people who later developed CD or UC.

    The story instead states that antibody diversity was significantly lower up to 10 years before diagnosis. That differs from the supplied profile’s abstract-level finding of increased repertoire variability up to approximately 4 years prediagnosis.

    From observational longitudinal cohort serology (PhIP-Seq); Longitudinal observational serological profiling (PhIP-Seq)

  • Responses to encapsulated bacteria such as Streptococcus pneumoniae, Haemophilus, and Neisseria progressively declined toward diagnosis.

    This secondary but material trajectory finding is not mentioned in the story.

    From longitudinal serological profiling (PhIP-Seq) in archived human cohort

6 things the story did carry across
  • Observational longitudinal PhIP-Seq serology design in a US military cohort: 2,000 archived serum samples from 200 future CD cases, 200 future UC cases, and 100 matched controls, collected up to 10 years before diagnosis.
  • Crohn’s disease-specific prediagnostic signatures included elevated herpesvirus/EBV-directed responses and anti-flagellin antibodies up to 10 years before diagnosis, especially in those who later developed complicated or ileal CD.
  • Ulcerative colitis-specific prediagnostic signatures involved combined antimicrobial, antiviral, and autoantibody patterns, including antibodies against MAP kinase-activating death domain protein.
  • The evidence is observational and identifies associations/trajectories before diagnosis, not causal effects.
  • Generalisability may be limited because the cohort is a US military tri-service population; validation in other and more diverse populations is needed.
  • Assay performance, reproducibility, clinical screening utility, and independent technical/clinical validation are not established in the abstract-level profile.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoCharacterise longitudinal prediagnostic serum antibody repertoires up to 10 years before IBD onset using PhIP-Seq in a US military cohort, and test whether repertoire variability and specific signatures change during the prodrome.observational longitudinal cohort serology (PhIP-Seq)Expand

In plain English

Observational longitudinal serology study applying PhIP-Seq to archived prediagnostic sera from a US military cohort (200 future CD, 200 future UC, 100 matched controls; 2000 samples total) collected up to 10 years before clinical IBD diagnosis to characterise antibody-repertoire trajectories and disease-specific serological signatures in the prodromal period.

Key findings

  • Antibody-repertoire variability was increased up to ~4 years before diagnosis in individuals who later developed Crohn's disease and ulcerative colitis.
  • Elevated herpesvirus-directed antibody responses, notably against Epstein–Barr virus, were detectable up to 10 years before diagnosis in individuals who later developed Crohn's disease.
“We applied PhIP-Seq to profile antibody responses in 2000 longitudinal serum samples from 200 individuals who developed Crohn's disease (CD), 200 who developed ulcerative colitis (UC) and 100 matched healthy controls”
What this piece can’t prove
  • Observational design: reported associations and temporal trajectories do not establish causality.

3 further details could not be confirmed from the summary.

2human in vivoIdentify Crohn’s disease–specific prediagnostic serological signatures (eg, herpesvirus/EBV-directed responses, anti-flagellin antibodies), and relate these signatures to later CD phenotype (eg, complicated or ileal disease).Longitudinal observational serological profiling (PhIP-Seq)Expand

In plain English

Within a longitudinal PhIP-Seq serology analysis of archived prediagnostic sera (up to 10 years before diagnosis) from a US military cohort, Crohn’s disease (pre-CD) shows disease-specific serological signatures: elevated herpesvirus-directed (notably Epstein–Barr virus) and anti-flagellin antibody responses detectable up to 10 years before diagnosis, with these signals particularly pronounced in participants who later developed complicated or ileal CD. Antibody-repertoire variability increased up to ~4 years before diagnosis in pre-CD, and responses to some encapsulated bacteria declined toward diagnosis.

Key findings

  • Herpesvirus-directed antibody responses, notably Epstein–Barr virus (EBV)-directed antibodies, were elevated in individuals who later developed Crohn’s disease, detectable up to 10 years before diagnosis and especially prominent in those who later developed complicated or ileal disease.
  • Anti-flagellin antibodies were elevated in prediagnostic sera of future CD cases up to 10 years before diagnosis, with stronger signals in individuals who subsequently developed complicated or ileal CD.
“Differential analyses revealed elevated herpesvirus-directed responses (notably Epstein-Barr virus) and anti-flagellin antibodies up to 10 years prediagnosis in CD, particularly in individuals who later developed complicated or ileal disease.”
What this piece can’t prove
  • Abstract lacks effect sizes, confidence intervals, p-values, and detailed subgroup sample counts needed to assess robustness and clinical relevance of reported associations.

4 further details could not be confirmed from the summary.

3human in vivoIdentify ulcerative colitis–specific prediagnostic serological signatures (combined antimicrobial/antiviral/autoantibody patterns, including MAP kinase-activating death domain protein antibodies).PhIP-Seq longitudinal serological cohort profilingExpand

In plain English

In a longitudinal PhIP-Seq serology study of archived prediagnostic sera from the US military cohort, individuals who later developed ulcerative colitis exhibited a combined antimicrobial, antiviral and autoantibody serological signature detectable prior to diagnosis; the abstract names antibodies against the MAP kinase-activating death domain protein as an example of the autoantibody component.

Key findings

  • Pre-UC sera displayed a combined antimicrobial, antiviral, and autoantibody signature detectable up to 10 years before diagnosis; the autoantibody component included antibodies against the MAP kinase-activating death domain protein.
“Pre-UC was characterised by combined antimicrobial, antiviral and autoantibody signatures, including antibodies against the MAP kinase-activating death domain protein.”
What this piece can’t prove
  • Summary is based on abstract-only information; full paper needed for statistical details, antigen lists, and reproducibility measures.

2 further details could not be confirmed from the summary.

4human in vivoDescribe progressive loss/decline of antibody responses to encapsulated bacteria (eg, S. pneumoniae, Haemophilus, Neisseria) toward diagnosis in individuals who develop IBD.longitudinal serological profiling (PhIP-Seq) in archived human cohortExpand

In plain English

Longitudinal serological profiling using PhIP-Seq of archived prediagnostic sera identified a progressive decline in antibody responses directed against encapsulated bacteria (examples cited: Streptococcus pneumoniae, Haemophilus, Neisseria) as individuals approached an IBD diagnosis. This trajectory was reported across pre-IBD individuals in the cohort and contrasted with other antibody trajectories (for example, increasing antiviral or anti-flagellin responses).

Key findings

  • Antibody responses to encapsulated bacteria (examples given: Streptococcus pneumoniae, Haemophilus, Neisseria) showed a progressive decline toward diagnosis in individuals who later developed IBD.
“In contrast, responses to encapsulated bacteria (eg, Streptococcus pneumoniae, Haemophilus, Neisseria) progressively declined towards diagnosis.”
What this piece can’t prove
  • Aggregation/grouping choices for encapsulated-bacteria targets and their impact on the result are not described.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

And 9 more candidates considered.